Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck & Co, Inc.
Mitsubishi Tanabe Pharma Corporation
Download the complete report: http://ift.tt/1sehHOW
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1 Disclaimers………….. I-2 Data Interpretation & Reporting Degree I-2 Quantitative Procedures & Analytics I-2 Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW………….. II-1 Outlook for DPP-IV Treatments Remains Robust II-1 Significant Events in the DPP-IV Inhibitor Area II-2 Table 1: Significant DPP-4 Inhibitors about the Market: List of Brand, Preparation, Manufacturer, Everyday Procedure Cost, FDA Approval Date and Patent Expiration Date II-3 TECOS Outcomes Prove Superiority of Januvia among Gliptins II-3 Sizable Potential Exists for Januvia and Various other DPP-4 Inhibitors II-3 Table 2: Global DPP-4 Inhibitor Market by Best 5 Drug Class (2015): Percentage Market Discuss Breakdown of Revenues (involves corresponding Graph/Chart) II-4 The Diabetes Epidemic…………..II-4 Global Diabetes Expenditure: Chance Indicator for DPP-IV Inhibitor Market………….. II-5 Table 3: Global Good health Expenditure about Diabetes by Region (2015): Investing (in US$ Billion) by Individuals Diagnosed along with Diabetes in the Age Group 20-79 Years to Handle Diabetes and Control Associated Complications (involves corresponding Graph/Chart)………….. II-5 Overview of Drug Courses in Anti-Diabetic Drugs Category II-5 Complex T2DM Administration Protocol and the Role of DPP-IV Inhibitors………….. II-6 DPP-4 Inhibitors – Complementing Existing Procedures II-7 Rationale for Usage of DPP-4 Inhibitors II-7 Comparison of Anti-Diabetic Drug Courses by HbAC1 Reduction II-8 Hunt for Novel Therapeutic Locations Attracts Pharma to DPP-4 Market II-8 DPP-4 Inhibitors versus GLP-1 Receptor Agonists II-8 Distinction in between GLP-1 Receptor Agonists and DPP-4 Inhibitors II-9 DPP-4 Inhibitors versus Sulfonylureas II-9
2. A REVIEW OF Pick APPROVED DRUGS, AND PIPELINE ANALYSIS II-10 The DPP-4 Inhibitor Domain…………..II-10 Pick Approved DPP-4 Inhibitors Offered in Created Markets II-11 Januvia – The Best DPP-IV Inhibitor Drug International II-11 Galvus Sales Garner Substantial Growth II-12 A Comparison of Januvia and Galvus II-12 Pharmacological Comparison of Sitagliptin and Vildagliptin II-12 Januvia® Franchise (Merck & Co.) II-12 Table 4: Global Sales of Januvia (Sitagliptin) Franchise by Region (2016E, 2018E, 2020E & 2022E): Value Sales in US$ Million for US and RoW(involves corresponding Graph/Chart) II-13 Implantable Drug Pump: Potential Threat to Januvia? II-13 Galvus (Novartis)………….. II-14 Onglyza (AstraZeneca)…………..II-14 Table 5: Global Sales of Onglyza (Saxagliptin) Franchise by Region (2016, 2018, 20twenty & 2022): Value Sales in US$ Million for US and Remainder of Globe (involves corresponding Graph/Chart) II-15 Tradjenta (Boehringer Ingelheim) II-15 TENELIA (Mitsubishi Tanabe Pharma Corporation & Daiichi Sankyo Co., Ltd.)………….. II-16 Nesina (Takeda Pharmaceutical) II-16 ZAFATEK (Takeda Pharmaceutical)…………..II-16 MARIZEV (Merck)………….. II-17 Pipeline Analysis………….. II-17 DPP-IV Inhibitor Pipeline…………..II-17 Dutogliptin Progress Shelved…………..II-18
3. DIABETES INCIDENCE AND PREVALENCE II-19 Table 6: Global Diabetes Mellitus Incidence among Ages 20-79 (2015 & 2040P): Prevalence (in Million) and Percentage Discuss by Geographic Region (involves corresponding Graph/Chart) II-19
Table 7: Best 10 Countries International along with the Highest Lot of Individuals (in the Age Group 20-79 Years) along with DM (in Millions): 2015 (involves corresponding Graph/Chart) II-twenty Diabetes Mellitus Cases International – A Demographic Analysis by Geographic Region…………..II-twenty Download the complete report: http://ift.tt/1sehHOW
About Reportbuyer
Reportbuyer is a Best industry intelligence solution that supplies all of market study reports from Best publishers
http://ift.tt/ORNIX1
For a lot more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To See the original version about PR Newswire, visit:http://ift.tt/22qQBAA
SOURCE ReportBuyer
